Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2017-12-22 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Issue of Equity
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a specific corporate action: 'Issue of Equity' involving the raising of £1.0 million through the issue of new ordinary shares and warrants. This is a typical announcement disseminated via a Regulatory Information Service (RIS). Since it is a specific corporate announcement that fits the definition of a general regulatory filing and is not a comprehensive report (like 10-K or IR), the most appropriate classification is RNS (Regulatory Filings), which serves as the general category for such announcements not covered by more specific codes like DIV or CAP, although this specific event relates to capital raising (CAP). However, given the explicit RNS formatting and the nature of the announcement being a brief update disseminated through the RIS system, RNS is a strong candidate. Reviewing the definitions, 'CAP' is for 'Updates on company fundraising, financing activities, or capital structure changes.' This document is precisely about fundraising (£1.0 million raised) and share issuance. Therefore, 'CAP' is more specific and accurate than the general 'RNS' fallback, even though it carries an RNS number. The document length is short (4705 chars), but it contains the full details of the transaction, not just an announcement that a report is attached, thus avoiding the RPA classification.
2017-12-22 English
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an RNS announcement from ValiRx PLC dated December 21, 2017. The primary content explicitly states the 'RESULT OF GENERAL MEETING' and confirms that 'all resolutions were passed.' This directly relates to the outcome of a shareholder vote at a general meeting. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). Although it is an RNS filing, the specific content points more strongly to DVA than the general RNS fallback.
2017-12-21 English
Warrant Exercise
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details the 'EXERCISE OF WARRANTS AND ISSUE OF EQUITY', resulting in new ordinary shares and an update to the total issued share capital, which directly relates to capital structure changes and share issuance. This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is an RNS announcement, the specific nature of the announcement (share issuance/capital change) makes SHA a more precise classification than the general fallback RNS.
2017-12-20 English
Warrant Exercise
Capital/Financing Update Classification · 1% confidence The document is identified by the 'RNS Number' header and contains an announcement regarding the 'EXERCISE OF WARRANTS AND ISSUE OF EQUITY'. This action directly relates to changes in the company's share capital and the resulting total number of shares, which falls under financing activities or capital structure changes. Specifically, it details the issuance of 400,000 new ordinary shares following warrant exercise, providing gross proceeds of £20,000, and mentions the resulting enlarged issued share capital for Disclosure and Transparency Rules purposes. This aligns best with the 'Capital/Financing Update' (CAP) definition, as it is a direct capital raising event. Although it is distributed via RNS, the core content is a specific capital event, making CAP more precise than the general RNS fallback.
2017-12-20 English
Warrant Exercise
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 18 December 2017. The content discusses the 'EXERCISE OF WARRANTS AND ISSUE OF EQUITY', resulting in new ordinary shares being admitted to trading on AIM. This is a specific corporate action announcement related to capital structure and share issuance. While it involves shares (suggesting SHA or POS), the primary nature of this announcement, distributed via the RNS system, is a general regulatory update concerning capital changes. Since the document explicitly details the issuance of new shares following warrant exercise and provides the resulting total issued share capital for DTR purposes, it strongly aligns with 'Share Issue/Capital Change' (SHA). However, given the context of it being a direct RNS release detailing a specific transaction (warrant exercise leading to new shares), and the presence of the RNS header, it is a specific regulatory filing. Comparing SHA (Share Issue/Capital Change) and POS (Transaction in Own Shares), this is an issuance due to warrant exercise, which fits SHA better than POS (which usually implies buybacks/treasury stock). Since it is a specific, non-miscellaneous regulatory announcement, SHA is the most precise fit over the general RNS fallback.
2017-12-18 English
re: VAL201 Clinical Trials
Regulatory Filings Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and explicitly states 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces regulatory approval (from MHRA and REC) for a clinical study enhancement, which is a specific corporate event announcement. While it contains financial/operational updates, its primary nature as a general regulatory announcement distributed via the London Stock Exchange's RNS system, and the lack of a specific category like 'ER' (Earnings Release) or 'CAP' (Financing Update), points towards the general regulatory filing category. Since it is a specific announcement distributed via RNS, and does not fit the definitions for ER, IR, 10-K, or other specific reports, RNS (Regulatory Filings) is the most appropriate fallback/general category for this type of market news release.
2017-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.